“MASCCC/ESMO 2023 Updated Consensus Recommendations for Preventing Chemotherapy-Induced Nausea and Vomiting”

https://pubmed.ncbi.nlm.nih.gov/38114821

The 2023 updated MASCC/ESMO Consensus recommendations advise using a triple combination of neurokinin (NK)1 receptor antagonist, 5-HT3 receptor antagonist, and steroids for patients undergoing carboplatin (AUC ≥ 5) and women < 50 years of age receiving oxaliplatin-based treatment, and limiting steroid administration to day 1 in moderately emetogenic chemotherapy regimens.